MedDataX Logo

Long Term Significance (Survival) of LCI in Patients With Cystic Fibrosis

NCT ID: NCT01951833

Last Updated: 2015-01-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-31

Study Completion Date

2017-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current dream in CF research is to discover safe drugs that correct the basic defect and prevent lung disease, allowing patients without significant lung damage to live nearly normal lives with a dramatic increase in life expectancy and without the burden of current treatment. The compound VX-770 (Ivacaftor Ò) is hoped to be the first milestone along this way. Progression of lung disease is now so gradual in many centres that sensitive indicators of early lung disease (small airways disease) are critically needed to assess the effects of such new treatments. In this context, assessment of ventilation inhomogeneity by the measurement called Lung clearance index (LCI) seems to be the most promising tool. However, to get approval by health authorities, new measures used in drug evaluation need to fulfill strict criteria. For LCI, the investigators still need to prove its long term significance: How well does the LCI measurement predict the long term lung disease course? Therefore, in this study the investigators want to measure LCI at baseline in a large patient cohort and establish how well it predicts the patients' disease course over the next 2 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation

NCT01262352

Cystic Fibrosis
COMPLETED PHASE2

A Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance Index

NCT02276898

Cystic Fibrosis
COMPLETED PHASE2

Tracking CF Lung Disease Through the Early Years: Utility of the LCI

NCT03138772

Observational
COMPLETED

Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor

NCT07314229

Cystic Fibrosis (CF) Mucoviscidosis
NOT_YET_RECRUITING NA

Rollover Study of VX-770 in Cystic Fibrosis Subjects

NCT01117012

Cystic Fibrosis
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with CF ( 6 years and older and FEV1 above 40% predicted) will be invited to participate in this prospective non interventional study in 2 CF centers ( UCL and UZ Leuven). Jointly we take care of more than 40 % of the Belgian CF population. Median FEV1 of children (6 - \<18 y, n \>120) from these CTN centers is high ( around 100% pred), defining a study group of great interest in the current context.

To assess the predictive value of LCI over 2 years, the time to next pulmonary exacerbation will be evaluated in the entire cohort. To assess the predictive value of LCI over 2 years, the time to next pulmonary exacerbation will be evaluated in the entire cohort.

Repeat LCI measurements will be done at subsequent patient visits.

2 devices measuring the LCI will be tested and compared : Ecomedics and NDD.

LCI and spirometry will be measured in 120 healthy Belgian children and young adults. These subjects must be free of respiratory symptoms for at least two weeks and will not have any chronic or recurrent chest problem.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis (CF)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cystic fibrosis (Ecomedics vs NDD)

No treatment, observational

EasyOne Pro and Ecomedics

Intervention Type DEVICE

LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics

Healthy (Ecomedics vs NDD)

Free of respiratory symptoms for at least two weeks and will not have any chronic or recurrent chest problem.

No treatment, observational

EasyOne Pro and Ecomedics

Intervention Type DEVICE

LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EasyOne Pro and Ecomedics

LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* FEV1(% predicted) \> 40%

Exclusion Criteria

* FEV1(% predicted) \< 40%
* Exacerbation during baseline measurement
Minimum Eligible Age

6 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

KU Leuven

OTHER

Sponsor Role collaborator

University Hospital St Luc, Brussels

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Poncin William

Physiotherapist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lebecque Patrick, PhD

Role: STUDY_DIRECTOR

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Poncin William

Role: PRINCIPAL_INVESTIGATOR

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cliniques Universitaires Saint-Luc (UCL)

Woluwé-Saint-Lambert, Brussels Capital, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LCI-01-St-Luc

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
NCT03768089 COMPLETED PHASE1/PHASE2
Evaluation of the Lung Clearance Index
NCT02342951 COMPLETED NA
Daily Monitoring of Respiratory Symptoms and Spirometry During ETI Treatment in Persons With Cystic Fibrosis.
NCT05599230 UNKNOWN
Lung Clearance Index (LCI) in Pediatric Patients With Obstructive Lung Disease
NCT02950116 TERMINATED NA
Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis Adults
NCT02368080 COMPLETED
Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects
NCT01208285 COMPLETED PHASE1
A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
NCT03029455 COMPLETED PHASE1
The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis
NCT00635141 COMPLETED PHASE3
Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis Children
NCT02378454 COMPLETED
A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation
NCT02742519 TERMINATED PHASE3
Inhaled Therapy Adherence and Outcomes to Kaftrio in Cystic Fibrosis
NCT05519020 COMPLETED
Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation
NCT01531673 COMPLETED PHASE2
VX-770 for the Treatment of Chronic Bronchitis
NCT03251911 WITHDRAWN PHASE4
Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis
NCT01347190 COMPLETED PHASE1
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
NCT03912233 COMPLETED PHASE2
Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis
NCT00671736 COMPLETED PHASE2
Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa
NCT02248922 TERMINATED PHASE4
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
NCT03911713 COMPLETED PHASE2
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older
NCT05153317 ACTIVE_NOT_RECRUITING PHASE3
Early Intervention in Cystic Fibrosis Exacerbation
NCT01104402 COMPLETED NA
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years
NCT04537793 COMPLETED PHASE3
Home Monitoring to Predict Exacerbation in Cystic Fibrosis
NCT02416375 COMPLETED
Prediction of Survival in Children With Cystic Fibrosis Using the Multiple-breath Washout
NCT04016194 COMPLETED
The Use of Novel Diagnostic Tools to Increase Detection of Early Fibrosis in Cystic Fibrosis Related Liver Disease to Improve Clinical Management
NCT04277819 COMPLETED
Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis
NCT04026360 RECRUITING